earnings
confidence high
sentiment negative
materiality 0.70
Charles River Q1 GAAP EPS $(0.30), non-GAAP $2.06; reaffirms FY2026 guidance
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
2026-Q1 EPS
reported -$0.30
vs consensus $1.96
▼ miss
(-115.3%)
- Q1 revenue $995.8M (+1.2% reported, -1.5% organic); GAAP loss $(0.30) vs $0.50 prior year.
- Non-GAAP EPS $2.06, down 12% YoY; non-GAAP operating margin 16.3% vs 19.1%.
- Completed divestiture of CDMO and Cell Solutions to GI Partners on May 6, 2026; European sites expected in May.
- Repurchased $200M of stock in Q1; $800M remaining under $1B authorization.
- Reaffirmed FY2026 organic revenue (-1.5% to -0.5%) and non-GAAP EPS $10.80-$11.30; lowered reported revenue outlook ~50bps due to FX.